title: No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma.
abstract: OBJECTIVE
  To report our long-term experience with the local toxicity profile and ocular motility changes after treatment of intraocular retinoblastoma with subtenon topotecan chemotherapy.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Ten eyes in 8 patients with retinoblastoma treated with subtenon topotecan.
  
  
  METHODS
  We assessed potential complications in ocular motility in eyes with retinoblastoma treated with subtenon topotecan using forced duction testing under general anaesthesia. Eyes subsequently enucleated because of treatment failure were examined histologically.
  
  
  RESULTS
  Ten eyes in 8 patients with retinoblastoma treated with 1 to 4 injections of subtenon topotecan were examined repeatedly, with a mean follow-up period of 37 months. Ocular motility remained normal in all eyes by forced duction, with no observed persistent conjunctival congestion, abnormal ocular motility, or enophthalmos in retained eyes 3 years after last injection. Histopathologic examination of the 2 enucleated eyes did not reveal signs of orbital tissue necrosis or fibrosis.
  
  
  CONCLUSIONS
  Unlike subtenon carboplatin, subtenon topotecan therapy is not associated with long-term toxicity affecting ocular muscles or orbital soft tissue. No effect on ocular motility was observed.
authors: Department of Ophthalmology and Visual Sciences, The Hospital for Sick Children, Toronto, Ont.
authors: Yacoub A
authors: YA
authors: Yousef
authors: William
authors: W
authors: Halliday
authors: Helen S L
authors: HS
authors: Chan
authors: Elise
authors: E
authors: Héon
authors: Brenda L
authors: BL
authors: Gallie
authors: Helen
authors: H
authors: Dimaras
mesh_terms: D002675:Child, Preschool; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D015353:Eye Enucleation; D053483:Eye Movement Measurements; D005133:Eye Movements / Q000187:drug effects / Q000502:physiology; D015718:Fibrin Tissue Adhesive / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007267:Injections; D015835:Ocular Motility Disorders / Q000139:chemically induced* / Q000503:physiopathology; D011183:Postoperative Complications; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D012175:Retinoblastoma / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D058475:Tenon Capsule / Q000187:drug effects*; D014014:Tissue Adhesives / Q000627:therapeutic use*; D059004:Topoisomerase I Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D015718:Fibrin Tissue Adhesive; D014014:Tissue Adhesives; D059004:Topoisomerase I Inhibitors; D019772:Topotecan